

Docket No.: 2003080-0205  
(SK 1071-US2)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

---

In re Patent Application of:  
Samuel J. Danishefsky

Application No.: 10/551,152

Confirmation No.: 4442

Filed: September 25, 2006

Art Unit: 1626

For: MIGRASTATIN ANALOGS AND USES  
THEREOF (COMPOSITIONS AND  
METHODS)

---

Examiner: Robert H. Havlin

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)); and includes herewith the fee set forth in §1.17(p).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is “prior art” for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Applicant hereby makes the following additional information of record in the above-identified application:

Applicant certifies that the Information Disclosure Statement *either*:

- ☒ Does not contain non-English language citations;
- ☐ Includes one or more translations of a non-English citation; or
- ☐ Does contain non-English language citations, of which the following is a concise explanation:
  - ☐ Includes an English Abstract and/or Title of a non-English citation.
  - ☐ Includes one or more translations of a non-English citation.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

A payment in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p) is being paid via the USPTO's electronic filing system's credit card payment option. For purposes of clarity, **no authorization is given to charge other fees not essential to maintenance of pendency.** Should the United States Patent and Trademark Office be of the view that such non-essential fees are owed, a Notice specifically itemizing and requesting payment of the fees is requested.

**Dated: October 21, 2009**

Respectfully submitted,

/Julie Anne Knight/

Julie Anne Knight

Registration No.: 48,867

CHOATE, HALL & STEWART, LLP

Two International Place

Boston, Massachusetts 02110

(617) 248-5227

Attorney for Applicant